annb0t
Top 20
Telix Pharmaceuticals Limited
MELBOURNE, Australia, March 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, âTelixâ, the âCompanyâ) today announces that ZIRCON (Zirconium in Renal Cancer Oncology, NCT03849118) a pivotal Phase III study of investigational renal (kidney) cancer imaging agent TLX250-CDx has dosed 252 patients, the target enrolment for the study. TLX250-CDx (89Zr-DFO-girentuximab) is an investigational product for the imaging of clear cell re...
>>> Read more: ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment
MELBOURNE, Australia, March 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, âTelixâ, the âCompanyâ) today announces that ZIRCON (Zirconium in Renal Cancer Oncology, NCT03849118) a pivotal Phase III study of investigational renal (kidney) cancer imaging agent TLX250-CDx has dosed 252 patients, the target enrolment for the study. TLX250-CDx (89Zr-DFO-girentuximab) is an investigational product for the imaging of clear cell re...
>>> Read more: ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment
